Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amneal pharmaceuticals inc - AMRX

AMRX

Close Chg Chg %
12.18 -0.24 -1.97%

Closed Market

11.94

-0.24 (1.97%)

Volume: 2.05M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Trade Now

Company Overview: amneal pharmaceuticals inc - AMRX

AMRX Key Data

Open

$12.18

 Day Range

11.71 - 12.22

52 Week Range

6.69 - 12.68

 Market Cap

$3.83B

Shares Outstanding

314.36M

 Public Float

156.64M

Beta

1.37

 Rev. Per Employee

N/A

P/E Ratio

845.07

 EPS

$0.02

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.84M

  

AMRX Performance

1 Week
 
 -4.63%
 
1 Month
 
 5.01%
 
3 Months
 
 24.12%
 
1 Year
 
 41.30%
 
5 Years
 
 183.61%
 

AMRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About amneal pharmaceuticals inc - AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRX At a Glance

Amneal Pharmaceuticals, Inc.
400 Crossing Boulevard
Bridgewater, New Jersey 08807
Phone 1-908-947-3120 Revenue 2.79B
Industry Pharmaceuticals: Major Net Income -116,886,000.00
Sector Health Technology 2024 Sales Growth 16.726%
Fiscal Year-end 12 / 2025 Employees 8,300
View SEC Filings

AMRX Valuation

P/E Current 845.07
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.876
Price to Book Ratio N/A
Price to Cash Flow Ratio 8.29
Enterprise Value to EBITDA 8.459
Enterprise Value to Sales 1.785
Total Debt to Enterprise Value 0.52

AMRX Efficiency

Revenue/Employee 336,621.325
Income Per Employee -14,082.651
Receivables Turnover 3.455
Total Asset Turnover 0.801

AMRX Liquidity

Current Ratio 1.405
Quick Ratio 0.863
Cash Ratio 0.105

AMRX Profitability

Gross Margin 36.523
Operating Margin 12.645
Pretax Margin -1.969
Net Margin -4.184
Return on Assets -3.352
Return on Equity N/A
Return on Total Capital -4.706
Return on Invested Capital -4.988

AMRX Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 104.399
Total Debt to Total Assets 74.059
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 90.70
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amneal Pharmaceuticals Inc - AMRX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.09B 2.21B 2.39B 2.79B
Sales Growth
+5.08% +5.67% +8.20% +16.73%
Cost of Goods Sold (COGS) incl D&A
1.30B 1.42B 1.54B 1.77B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
233.41M 240.18M 229.40M 236.19M
Depreciation
60.70M 68.11M 66.20M 62.60M
Amortization of Intangibles
172.70M 172.06M 163.20M 173.59M
COGS Growth
-2.07% +8.79% +8.50% +15.39%
Gross Income
791.66M 795.82M 856.66M 1.02B
Gross Income Growth
+19.41% +0.52% +7.65% +19.12%
Gross Profit Margin
+37.81% +35.97% +35.79% +36.52%
2021 2022 2023 2024 5-year trend
SG&A Expense
567.35M 595.39M 593.63M 667.15M
Research & Development
201.85M 195.69M 163.95M 190.71M
Other SG&A
365.50M 399.70M 429.68M 476.44M
SGA Growth
+11.98% +4.94% -0.30% +12.39%
Other Operating Expense
- - - -
-
Unusual Expense
71.60M 299.61M 100.61M 103.96M
EBIT after Unusual Expense
152.72M (99.18M) 162.43M 249.33M
Non Operating Income/Expense
14.97M 9.43M 7.93M (45.74M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
136.32M 158.38M 210.63M 258.60M
Interest Expense Growth
-6.63% +16.18% +32.99% +22.77%
Gross Interest Expense
136.32M 158.38M 210.63M 258.60M
Interest Capitalized
- - - -
-
Pretax Income
31.37M (248.13M) (40.27M) (55.01M)
Pretax Income Growth
+187.66% -891.07% +83.77% -36.61%
Pretax Margin
+1.50% -11.22% -1.68% -1.97%
Income Tax
11.20M 6.66M 8.45M 18.86M
Income Tax - Current - Domestic
1.31M (1.07M) 2.47M 8.31M
Income Tax - Current - Foreign
9.88M 7.74M 5.98M 10.55M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
20.17M (254.79M) (48.72M) (73.88M)
Minority Interest Expense
9.55M (124.80M) 35.27M 43.01M
Net Income
10.62M (129.99M) (83.99M) (116.89M)
Net Income Growth
-88.33% -1,323.51% +35.38% -39.16%
Net Margin Growth
+0.51% -5.88% -3.51% -4.18%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
10.62M (129.99M) (83.99M) (116.89M)
Preferred Dividends
- - - -
-
Net Income Available to Common
10.62M (129.99M) (83.99M) (116.89M)
EPS (Basic)
0.0713 -0.8612 -0.4769 -0.3783
EPS (Basic) Growth
-88.46% -1,307.85% +44.62% +20.68%
Basic Shares Outstanding
148.92M 150.94M 176.14M 308.98M
EPS (Diluted)
0.07 -0.8612 -0.4769 -0.3783
EPS (Diluted) Growth
-88.55% -1,330.29% +44.62% +20.68%
Diluted Shares Outstanding
151.82M 150.94M 176.14M 308.98M
EBITDA
457.72M 440.61M 492.44M 589.48M
EBITDA Growth
+16.85% -3.74% +11.76% +19.71%
EBITDA Margin
+21.86% +19.92% +20.57% +21.10%

Snapshot

Average Recommendation BUY Average Target Price 13.50
Number of Ratings 4 Current Quarters Estimate 0.18
FY Report Date 12 / 2025 Current Year's Estimate 0.799
Last Quarter’s Earnings 0.17 Median PE on CY Estimate N/A
Year Ago Earnings 0.58 Next Fiscal Year Estimate 0.942
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 3 4 4
Mean Estimate 0.18 0.19 0.80 0.94
High Estimates 0.20 0.21 0.82 1.03
Low Estimate 0.16 0.18 0.78 0.89
Coefficient of Variance 12.78 7.90 3.02 6.79

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Amneal Pharmaceuticals Inc - AMRX

Date Name Shares Transaction Value
May 20, 2025 Nikita Shah Executive Vice President 388,929 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.58 per share 2,948,081.82
Apr 2, 2025 Tushar Patel 48,578,209 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.35 per share 405,628,045.15
Mar 6, 2025 Andrew S. Boyer Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Anastasios G. Konidaris Executive Vice President & CFO 793,061 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Anastasios G. Konidaris Executive Vice President & CFO 611,902 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.76 per share 5,360,261.52
Mar 6, 2025 Jason B. Daly EVP, Chief Legal Officer 107,640 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Anastasios G. Konidaris Executive Vice President & CFO 578,936 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.76 per share 5,071,479.36
Mar 6, 2025 Anastasios G. Konidaris Executive Vice President & CFO 595,309 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 114,582 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 97,033 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 194,064 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 315,555 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 99,389 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 39,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 415,106 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.84 per share 3,669,537.04
Mar 6, 2025 Andrew S. Boyer Executive Vice President 434,643 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 396,449 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.76 per share 3,472,893.24
Mar 6, 2025 Andrew S. Boyer Executive Vice President 476,758 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Andrew S. Boyer Executive Vice President 319,753 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.76 per share 2,801,036.28
Mar 6, 2025 Andrew S. Boyer Executive Vice President 345,172 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Amneal Pharmaceuticals Inc in the News